Psyence Biomedical Ltd. (PBM)

Psyence Biomedical Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Selling, General & Admin	3.4	3.32	1.8	1.63
Depreciation & Amortization Expenses	0.01	0	0	-
Research & Development	0.75	0.34	0.95	1.61
Total Operating Expenses	4.15	3.66	2.75	3.23
Operating Income	-4.15	-3.66	-2.75	-3.23
Interest Income	0.2	0.1	0	0
Interest Expense	-0.01	-0.01	-0.05	-
Other Non-Operating Income (Expense)	-0.78	4.59	-48.36	0.03
Total Non-Operating Income (Expense)	-0.59	4.67	-48.41	0.03
Pretax Income	-4.74	1.01	-51.16	-3.21
Net Income	-3.94	1.01	-51.16	-3.21
Net Income to Common	-3.94	1.01	-51.16	-3.21
Shares Outstanding (Basic)	0	0	0	0
Shares Outstanding (Diluted)	0	0	0	0
Shares Change (YoY)	831.86%	1670.55%	30.34%	-
EPS (Basic)	-618.25	32.75	-29214.10	-2462.88
EPS (Diluted)	-618.13	32.75	-29214.10	-2462.88
Shares Outstanding	0.3	0.09	0	-
Free Cash Flow	-3.68	-3.74	-2.95	-1.59
Free Cash Flow Per Share	-32.47	-121.22	-1691.67	-1189.54
EBITDA	-4.15	-3.66	-2.75	-3.23
EBIT	-4.15	-3.66	-2.75	-3.23

Updated Nov 20, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q